Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Progression‐free survival · adults with cancer receiving anthracyclines
Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).
3 findings from 1 review
Partial response (partial or complete response) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete or partial… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Quality of life · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
GI function · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft health · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
GI function · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft health · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · patients with coronary heart disease
Smoking cessation probably leads to lower death from cardiovascular disease at 19 months to 126 months compared with continuous smoking (moderate certainty).
1 finding from 1 review
MACE · patients with coronary heart disease
Smoking cessation may leads to lower major adverse cardiovascular events (MACE) at 19 months to 110 months compared with continuous smoking (low certainty).
1 finding from 1 review
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab probably leads to lower infection with SARS‐CoV‐2 within 6 months compared with placebo (moderate certainty).
1 finding from 1 review
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower infection with SARS‐CoV‐2 within 6 monthsa compared with placebo (low certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
1 finding from 1 review